Pelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared with radical prostatectomy, a large retrospective review showed. Second pelvic malignancy -- ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Brachytherapy may provide an effective alternative treatment for younger men who are reluctant to undergo surgery for favorable risk prostate cancer, according to Canadian researchers. Juanita Crook, ...

There are no randomized trials to guide treatment decisions between radiotherapeutic and surgical options for patients with high-risk localized prostate cancer. Comparative studies have been limited ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers We analyzed claims for Medicare-enrolled men older than age 65 years living in Surveillance, Epidemiology, and End ...

Becker’s ASC Review sat down with Randy Whaley, director of business development for United Medical Systems, to tackle a reader’s question about what is needed for an ASC to be able to offer and ...

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function. A prostate cancer journey can involve plenty of questions.